-
Article
Open AccessA Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose ...
-
Article
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
Little qualitative research exploring the impact of multiple myeloma (MM) and its treatment on the health-related quality of life (HRQL) of patients has been published. This study aimed to explore the burden o...
-
Article
Open AccessA phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended doses of ...
-
Article
Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore…if you have myeloma’
-
Article
PKC Regulates Dual Coupling of β1-Adrenoreceptors to the L-Type Ca2+ Channels
-
Article
Pharmacological Evidence that Calcium is Not Required for P2-Receptor-Stimulated Cl− Secretion in HT29-Cl.16E
Extracellular ATP at micro- to millimolar concentrations activates Cl− conductance and increases cytosolic calcium ([Ca] i ) in many epithelial cells, including the colonic epit...
